← All trials
NCT05733286
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2023
- Primary completion
- Sep 30, 2025
- Completion date
- Oct 31, 2025
- First posted
- Feb 17, 2023
- Last posted
- Jul 14, 2023
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- MerckCollaborator
- Duke UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.